Clinical trials: Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Hodgkin's Lymphoma
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL)…
- Trial name
- NCT00312845
- Testing
- Bortezomib + Rituximab, Rituximab
- Where
- 206 sites in United States, Argentina and 30 more
- Volunteers
- 676 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT04830137
- Testing
- NX-2127
- Where
- 16 sites in United States
- Volunteers
- 248 people
- Sponsor
- Nurix Therapeutics, Inc.
B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding…
- Conditions
- B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03479268
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- EPCORE™ NHL-3 (NCT04542824)
- Testing
- Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- Where
- 15 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Genmab
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Follicular Lymphoma
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
- Trial name
- ELARA (NCT03568461)
- Testing
- tisagenlecleucel
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Follicular Lymphoma
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
- Trial name
- NCT07187960
- Testing
- TQB2825 Injection, Rituximab Injection
- Where
- 28 sites in China
- Volunteers
- 228 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Follicular Lymphoma
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or refractory to either chemotherapy or radioimmunotherapy…
- Trial name
- NCT04707079
- Testing
- Duvelisib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Lymphoma
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00182650
- Testing
- aldesleukin, rituximab, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma
- Trial name
- NCT06784726
- Testing
- Odronextamab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Follicular Lymphoma
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
- Trial name
- NCT05867030
- Testing
- lenalidomide, rituximab, parsaclisib
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D).
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma, Follicular Lymphoma Grade 3A
- Trial name
- NCT05326243
- Testing
- CD19-targeted chimeric antigen receptor T-cell
- Where
- 5 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
Lymphoid Malignancies, Multiple Myeloma
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest.
- Conditions
- Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Trial name
- PDX+Romi (NCT01947140)
- Testing
- Pralatrexate, Romidepsin
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Jennifer Amengual
Follicular Lymphoma
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as measured by overall response rate (ORR) in adult participants with relapsed and/or refractory follicular lymphoma (FL).
- Trial name
- NCT01939899
- Testing
- IXAZOMIB
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 29 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00806767
- Testing
- therapeutic immune globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes
Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006125
- Testing
- doxorubicin hydrochloride, topotecan hydrochloride
- Where
- 76 sites in United States, Puerto Rico
- Sponsor
- Alliance for Clinical Trials in Oncology
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.